Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 2
1970 2
1971 1
1976 1
1981 3
1982 4
1983 1
1984 3
1985 6
1986 3
1987 5
1988 6
1989 6
1990 6
1991 7
1992 17
1993 21
1994 11
1995 14
1996 18
1997 19
1998 23
1999 29
2000 41
2001 30
2002 29
2003 46
2004 39
2005 43
2006 41
2007 37
2008 42
2009 47
2010 43
2011 44
2012 50
2013 47
2014 66
2015 68
2016 89
2017 83
2018 90
2019 73
2020 70
2021 82
2022 71
2023 79
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

1,433 results

Results by year

Filters applied: . Clear all
Page 1
Multiple system atrophy.
Poewe W, Stankovic I, Halliday G, Meissner WG, Wenning GK, Pellecchia MT, Seppi K, Palma JA, Kaufmann H. Poewe W, et al. Nat Rev Dis Primers. 2022 Aug 25;8(1):56. doi: 10.1038/s41572-022-00382-6. Nat Rev Dis Primers. 2022. PMID: 36008429 Review.
Multiple system atrophy (MSA) is a rare neurodegenerative disease that is characterized by neuronal loss and gliosis in multiple areas of the central nervous system including striatonigral, olivopontocerebellar and central autonomic structures. …
Multiple system atrophy (MSA) is a rare neurodegenerative disease that is characterized by neuronal loss and gliosis in …
The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy.
Wenning GK, Stankovic I, Vignatelli L, Fanciulli A, Calandra-Buonaura G, Seppi K, Palma JA, Meissner WG, Krismer F, Berg D, Cortelli P, Freeman R, Halliday G, Höglinger G, Lang A, Ling H, Litvan I, Low P, Miki Y, Panicker J, Pellecchia MT, Quinn N, Sakakibara R, Stamelou M, Tolosa E, Tsuji S, Warner T, Poewe W, Kaufmann H. Wenning GK, et al. Mov Disord. 2022 Jun;37(6):1131-1148. doi: 10.1002/mds.29005. Epub 2022 Apr 21. Mov Disord. 2022. PMID: 35445419 Free PMC article. Review.
BACKGROUND: The second consensus criteria for the diagnosis of multiple system atrophy (MSA) are widely recognized as the reference standard for clinical research, but lack sensitivity to diagnose the disease at early stages. ...
BACKGROUND: The second consensus criteria for the diagnosis of multiple system atrophy (MSA) are widely recognized as t …
Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment.
Calandra-Buonaura G, Alfonsi E, Vignatelli L, Benarroch EE, Giannini G, Iranzo A, Low PA, Martinelli P, Provini F, Quinn N, Tolosa E, Wenning GK, Abbruzzese G, Bower P, Antonini A, Bhatia KP, Bonavita J, Pellecchia MT, Pizzorni N, Tison F, Ghorayeb I, Meissner WG, Ozawa T, Pacchetti C, Pozzi NG, Vicini C, Schindler A, Cortelli P, Kaufmann H. Calandra-Buonaura G, et al. Parkinsonism Relat Disord. 2021 May;86:124-132. doi: 10.1016/j.parkreldis.2021.03.027. Epub 2021 Mar 30. Parkinsonism Relat Disord. 2021. PMID: 33839029 Free article. Review.
Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by a combination of autonomic failure plus cerebellar syndrome and/or parkinsonism. ...
Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by a combination of autonomic failure plus …
Multiple system atrophy.
Goh YY, Saunders E, Pavey S, Rushton E, Quinn N, Houlden H, Chelban V. Goh YY, et al. Pract Neurol. 2023 Jun;23(3):208-221. doi: 10.1136/pn-2020-002797. Epub 2023 Mar 16. Pract Neurol. 2023. PMID: 36927875 Free PMC article. Review.
This is a practical guide to diagnosing and managing multiple system atrophy (MSA). We explain the newly published Movement Disorders Society Consensus Diagnostic Criteria, which include new 'Clinically Established MSA' and 'Possible Prodromal MSA' categories …
This is a practical guide to diagnosing and managing multiple system atrophy (MSA). We explain the newly published Move …
Multiple system atrophy: at the crossroads of cellular, molecular and genetic mechanisms.
Stefanova N, Wenning GK. Stefanova N, et al. Nat Rev Neurosci. 2023 Jun;24(6):334-346. doi: 10.1038/s41583-023-00697-7. Epub 2023 Apr 21. Nat Rev Neurosci. 2023. PMID: 37085728 Review.
Multiple system atrophy (MSA) is a rare oligodendroglial alpha-synucleinopathy characterized by neurodegeneration in striatonigral and olivopontocerebellar regions and autonomic brain centres. ...
Multiple system atrophy (MSA) is a rare oligodendroglial alpha-synucleinopathy characterized by neurodegeneration in st …
Multiple system atrophy.
Fanciulli A, Stankovic I, Krismer F, Seppi K, Levin J, Wenning GK. Fanciulli A, et al. Int Rev Neurobiol. 2019;149:137-192. doi: 10.1016/bs.irn.2019.10.004. Epub 2019 Nov 21. Int Rev Neurobiol. 2019. PMID: 31779811 Review.
Multiple system atrophy (MSA) is a sporadic, adult-onset, relentlessly progressive neurodegenerative disorder, clinically characterized by various combinations of autonomic failure, parkinsonism and ataxia. The neuropathological hallmark of MSA are glial cyto …
Multiple system atrophy (MSA) is a sporadic, adult-onset, relentlessly progressive neurodegenerative disorder, clinical …
Multiple-system atrophy.
Fanciulli A, Wenning GK. Fanciulli A, et al. N Engl J Med. 2015 Jan 15;372(3):249-63. doi: 10.1056/NEJMra1311488. N Engl J Med. 2015. PMID: 25587949 Review. No abstract available.
Neuropathology and molecular diagnosis of Synucleinopathies.
Koga S, Sekiya H, Kondru N, Ross OA, Dickson DW. Koga S, et al. Mol Neurodegener. 2021 Dec 18;16(1):83. doi: 10.1186/s13024-021-00501-z. Mol Neurodegener. 2021. PMID: 34922583 Free PMC article. Review.
Synucleinopathies can be divided into two major disease entities: Lewy body disease and multiple system atrophy (MSA). Common clinical presentations of Lewy body disease are Parkinson's disease (PD), PD with dementia, and dementia with Lewy bodies (DLB), whil …
Synucleinopathies can be divided into two major disease entities: Lewy body disease and multiple system atrophy (MSA). …
Monitoring α-synuclein aggregation.
Estaun-Panzano J, Arotcarena ML, Bezard E. Estaun-Panzano J, et al. Neurobiol Dis. 2023 Jan;176:105966. doi: 10.1016/j.nbd.2022.105966. Epub 2022 Dec 15. Neurobiol Dis. 2023. PMID: 36527982 Free PMC article. Review.
Synucleinopathies, including Parkinson's disease (PD), dementia with Lewy Bodies (DLB), and multiple system atrophy (MSA), are characterized by the misfolding and subsequent aggregation of alpha-synuclein (alpha-syn) that accumulates in cytoplasmic inclusions …
Synucleinopathies, including Parkinson's disease (PD), dementia with Lewy Bodies (DLB), and multiple system atrophy (MS …
Pharmacologic treatment of orthostatic hypotension.
Park JW, Okamoto LE, Shibao CA, Biaggioni I. Park JW, et al. Auton Neurosci. 2020 Dec;229:102721. doi: 10.1016/j.autneu.2020.102721. Epub 2020 Aug 28. Auton Neurosci. 2020. PMID: 32979782 Free PMC article. Review.
., those with impaired central autonomic pathways but spared peripheral noradrenergic fibers (multiple system atrophy) and normal or slightly reduced plasma norepinephrine, tend to respond better to "norepinephrine enhancers" (pyridostigmine, atomoxetine, and …
., those with impaired central autonomic pathways but spared peripheral noradrenergic fibers (multiple system atrophy) …
1,433 results